Review Article
Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease
Table 1
List of drugs and agents as candidates for the treatment of NAFLD.
| Insulin sensitizers | | Metformin (Biguanide) | | Thiazolidines (Pioglitazone, Rosiglitazone) | | Antioxidants | | Vitamin E | | Vitamin C | | Polyphenols (Resveratrol, etc.) | | Hepatocyte-protective agents | | Ursodeoxycholic acid | | n-3 polyunsaturated fatty acids (EPA and DHA) | | Antidyslipidemia | | Statins | | Fibrates | | NPC1L1 inhibitors (ezetimibe) | | RAS blockers | | Angiotensin II receptor blockers | | Angiotensin-converting enzyme inhibitors | | Antialdosterone (spironolactone and eplerenone) | | Renin inhibitor (aliskiren) | | Incretin-related agents | | GLP-1 agonists/analogs (exenatide and liraglutide) | | DPP-4 inhibitors (sitagliptin and vildagliptin) | | Antiobesity drugs | | Orlistat | | Sibutramine | | Mazindol | |
|
|